Oppenheimer analyst Jeff Jones lowered the firm’s price target on Seres Therapeutics to $4 from $5 and keeps an Outperform rating on the shares following Q1 results and a business update. The firm notes net sales of Vowst for the quarter were $10.1M, a disappointing 3% drop from Q4 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB: